Impact of a Personalized Medication Plan on Duration of Treatment With Potent Opioids in Acute Non-cancer Musculoskeletal Pain.
Not Applicable
Recruiting
- Conditions
- Acute Pathology of the Locomotor System
- Interventions
- Other: personalized pharmaceutical plan
- Registration Number
- NCT05905146
- Lead Sponsor
- University Hospital, Rouen
- Brief Summary
The aim of this study is to evaluate whether patients who benefit from a personalized pharmaceutical plan (PPP) during their hospitalization, allowing them to be informed and sensitized, are treated for a shorter period of time with strong opioids with a reduced risk of dependence compared to a management according to the usual modalities in the rheumatology services concerned.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
- Patient hospitalized in the rheumatology department
- Patient with acute pain in the context of a non-cancerous, non-traumatic, high-energy musculoskeletal pathology
- Patient for whom a prescription of strong opioid derivatives is initiated in rheumatology or patient for whom a prescription of strong opioid derivatives is maintained in rheumatology if the initial prescription has a maximum duration of 30 consecutive days prior to inclusion
Exclusion Criteria
- Patient with cancer or fibromyalgia already diagnosed at inclusion
- Patient with poor French language skills
- Taking a strong opioid treatment for more than 30 consecutive days prior to inclusion
- Person judged by the prescriber or pharmacist as not autonomous for the management of strong opioid treatment
- Patient already included in the study
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description interventional group personalized pharmaceutical plan benefiting from a multi-professional intervention around the strong opioid treatment with the aim of setting up a personalized pharmaceutical plan
- Primary Outcome Measures
Name Time Method total duration of treatment in days with strong opioids from day of inclusion 6 months
- Secondary Outcome Measures
Name Time Method pain assessment (numerical scale) at first patient call after stopping strong opioids 6 months number of patients exceeding the optimal duration of treatment with strong opioids defined by the SFETD learned society (French Society for the Study and Treatment of Pain) (3 months) 3 months number of patients exceeding the optimal duration of treatment with strong opioids defined by the CLUD (Pain Control Committee) of Rouen University Hospital (28 days) 28 days
Trial Locations
- Locations (3)
CHU de Lille
🇫🇷Lille, France
CHU de Nimes
🇫🇷Nîmes, France
CHU de ROUEN
🇫🇷Rouen, France